Inside Helus Pharma's Phase 3 Depression Trial

Helus Pharma CEO Eric So presents the development status of HLP003, a deuterated adjunctive depression treatment currently moving through Phase 3 clinical trials. The company distinguishes its approach through chemical modification designed to reduce drug-drug interactions and improve metabolic control compared to standard serotonergic antidepressants. The current data shows an immediate 74% remission rate after a two-dose regimen, with 100% response and 71% remission rates maintained at 12 months. HLP003 is positioned to allow patients to remain on existing background medications without requiring a washout period, a procedural barrier prevalent in standard psychiatric treatments. The company aims for drug approval in 2028, bolstered by a breakthrough therapy designation and their potential inclusion in the FDA priority voucher program.